3D Medicines Inc. (HKG:1244)

3D Medicines Statistics

Total Valuation

3D Medicines has a market cap or net worth of HKD 1.45 billion. The enterprise value is 724.03 million.

Market Cap	1.45B
Enterprise Value	724.03M

Important Dates

The next estimated earnings date is Monday, August 25, 2025.

Earnings Date	Aug 25, 2025
Ex-Dividend Date	n/a

Share Statistics

3D Medicines has 244.97 million shares outstanding. The number of shares has increased by 7.22% in one year.

Current Share Class	244.97M
Shares Outstanding	244.97M
Shares Change (YoY)	+7.22%
Shares Change (QoQ)	-0.07%
Owned by Insiders (%)	14.84%
Owned by Institutions (%)	5.39%
Float	171.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.06
PB Ratio	1.94
P/TBV Ratio	1.74
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-3.72
EV / Sales	1.53
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.66

Financial Position

The company has a current ratio of 2.02, with a Debt / Equity ratio of 0.34.

Current Ratio	2.02
Quick Ratio	1.98
Debt / Equity	0.34
Debt / EBITDA	n/a
Debt / FCF	-0.93
Interest Coverage	-12.99

Financial Efficiency

Return on equity (ROE) is -25.33% and return on invested capital (ROIC) is -7.37%.

Return on Equity (ROE)	-25.33%
Return on Assets (ROA)	-5.83%
Return on Invested Capital (ROIC)	-7.37%
Return on Capital Employed (ROCE)	-16.94%
Revenue Per Employee	2.48M
Profits Per Employee	-1.02M
Employee Count	191
Asset Turnover	0.34
Inventory Turnover	17.05

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +44.99% in the last 52 weeks. The beta is 0.85, so 3D Medicines's price volatility has been lower than the market average.

Beta (5Y)	0.85
52-Week Price Change	+44.99%
50-Day Moving Average	4.24
200-Day Moving Average	3.32
Relative Strength Index (RSI)	78.78
Average Volume (20 Days)	416,577

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, 3D Medicines had revenue of HKD 474.25 million and -194.38 million in losses. Loss per share was -0.79.

Revenue	474.25M
Gross Profit	395.59M
Operating Income	-131.35M
Pretax Income	-212.17M
Net Income	-194.38M
EBITDA	-121.87M
EBIT	-131.35M
Loss Per Share	-0.79

Balance Sheet

The company has 894.95 million in cash and 252.87 million in debt, giving a net cash position of 642.08 million or 2.62 per share.

Cash & Cash Equivalents	894.95M
Total Debt	252.87M
Net Cash	642.08M
Net Cash Per Share	2.62
Equity (Book Value)	748.87M
Book Value Per Share	3.41
Working Capital	532.05M

Cash Flow

In the last 12 months, operating cash flow was -224.09 million and capital expenditures -48.27 million, giving a free cash flow of -272.36 million.

Operating Cash Flow	-224.09M
Capital Expenditures	-48.27M
Free Cash Flow	-272.36M
FCF Per Share	-1.11

Margins

Gross margin is 83.42%, with operating and profit margins of -27.70% and -40.99%.

Gross Margin	83.42%
Operating Margin	-27.70%
Pretax Margin	-44.74%
Profit Margin	-40.99%
EBITDA Margin	-25.70%
EBIT Margin	-27.70%
FCF Margin	n/a

Dividends & Yields

3D Medicines does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.22%
Shareholder Yield	n/a
Earnings Yield	-13.38%
FCF Yield	-18.75%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

3D Medicines has an Altman Z-Score of -3.29 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.29
Piotroski F-Score	2